Spyre Therapeutics Book Value Per Share vs. EBITDA
| SYRE Stock | 28.43 0.68 2.45% |
Book Value Per Share | First Reported 2010-12-31 | Previous Quarter 26.68033432 | Current Value 25.35 | Quarterly Volatility 61.70803061 |
For Spyre Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Spyre Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Spyre Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Spyre Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Spyre Therapeutics over time as well as its relative position and ranking within its peers.
Spyre |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spyre Therapeutics. If investors know Spyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (37.90) | Return On Assets (0.39) | Return On Equity (0.92) |
The market value of Spyre Therapeutics is measured differently than its book value, which is the value of Spyre that is recorded on the company's balance sheet. Investors also form their own opinion of Spyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spyre Therapeutics' market value can be influenced by many factors that don't directly affect Spyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Spyre Therapeutics EBITDA vs. Book Value Per Share Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Spyre Therapeutics's current stock value. Our valuation model uses many indicators to compare Spyre Therapeutics value to that of its competitors to determine the firm's financial worth. Spyre Therapeutics is currently regarded as top stock in book value per share category among its peers. It also is currently regarded as top stock in ebitda category among its peers . At present, Spyre Therapeutics' Book Value Per Share is projected to decrease significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Spyre Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Spyre EBITDA vs. Book Value Per Share
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Spyre Therapeutics |
| = | 3.34 X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Spyre Therapeutics |
| = | (242.3 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Spyre EBITDA Comparison
Spyre Therapeutics is currently under evaluation in ebitda category among its peers.
Spyre Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Spyre Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Spyre Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Spyre Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Spyre Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 302 K | 317.1 K | |
| Operating Income | -242.3 M | -230.2 M | |
| Income Before Tax | -338.8 M | -321.9 M | |
| Total Other Income Expense Net | -96.5 M | -91.7 M | |
| Net Loss | -338.8 M | -321.9 M | |
| Net Interest Income | 6.1 M | 6.5 M | |
| Interest Income | 6.1 M | 6.5 M | |
| Net Loss | -338.8 M | -321.9 M | |
| Income Tax Expense | -26 K | -27.3 K | |
| Net Loss | (49.12) | (51.58) | |
| Income Quality | 0.29 | 0.28 | |
| Net Income Per E B T | 1.00 | 1.10 |
Spyre Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Spyre Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Spyre Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Spyre Therapeutics' important profitability drivers and their relationship over time.
Use Spyre Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Spyre Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spyre Therapeutics will appreciate offsetting losses from the drop in the long position's value.Spyre Therapeutics Pair Trading
Spyre Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Spyre Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Spyre Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Spyre Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Spyre Therapeutics to buy it.
The correlation of Spyre Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Spyre Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Spyre Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Spyre Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Spyre Therapeutics position
In addition to having Spyre Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Driverless Cars Thematic Idea Now
Driverless Cars
It encompasses large technology companies, automotive makers, security firms, and thematic ETFs across multiple industries. These entities are directly or indirectly involved in shaping the development and marketing of self-driving vehicles. The Driverless Cars theme has 36 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Driverless Cars Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
To fully project Spyre Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Spyre Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Spyre Therapeutics' income statement, its balance sheet, and the statement of cash flows.